NRX Pharmaceuticals, Inc. (NRXP) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. NRX Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for central nervous system disorders. The company operates two primary segments: drug development (NRX-100, NRX-101, KETAFREE) and clinical services through its subsidiary, HOPE Therapeutics. Following the acquisition of Dura Medical, LLC in September 2025, the company began generating patient service revenue. As of March 31, 2026, the company had a stockholders' deficit of $13.8 million and a working capital deficit of $17.8 million.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Patient Service Revenue | $1,068 | $0 |
| Net Loss | $(1,430) | $(5,512) |
| Net Loss Per Share (Basic/Diluted) | $(0.04) | $(0.34) |
| Operating Expenses | $5,810 | $3,847 |
| Cash and Cash Equivalents (End of Period) | $6,713 | $5,548 |
| Net Cash Used in Operating Activities | $(4,295) | $(3,480) |
| Net Cash Provided by Financing Activities | $3,424 | $7,585 |
| Total Liabilities | $25,719 | $28,893 |
| Warrant Liabilities | $8,766 | $12,304 |
Material Changes vs. Prior Period
- Revenue Generation: The company recorded $1.1 million in revenue in Q1 2026, compared to zero in Q1 2025, driven by the operations of the acquired Dura Medical clinics.
- Net Loss Reduction: Net loss decreased significantly to $1.4 million from $5.5 million in the prior year. This improvement was primarily due to a $3.5 million non-cash gain from the change in fair value of warrant liabilities, compared to a $2.9 million loss in the prior year.
- Operating Expenses: Total operating expenses increased by $1.96 million to $5.8 million. This includes new costs of patient services ($0.6 million) and increased R&D ($1.3 million) and SG&A ($3.8 million) expenses.
- Debt Status: All Anson Convertible Promissory Notes were fully converted to common stock by the end of 2025; no convertible notes remained outstanding as of March 31, 2026.
Outlook, Risks, and Management Commentary
- Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for at least twelve months from the filing date due to recurring operating losses and a working capital deficit. The company relies on additional equity or debt financing to fund operations.
- Drug Development Pipeline:
- KETAFREE: ANDA filed with priority review requested; FDA inspection status is "VAI." Commercial manufacturing initiated.
- NRX-100: NDA expected to be filed in Q2 2026. Management is leveraging Real World Evidence (RWE) and a Presidential Executive Order to support approval.
- NRX-101: NDA initiated for suicidal bipolar depression. A new Phase 2b/3 trial (MIND1) is approved to test NRX-101 in conjunction with TMS for depression and PTSD, supported by potential non-dilutive government funding.
- Strategic Acquisitions: The company acquired GeNeuro assets (including patents for schizophrenia and ALS treatments) in May 2026 (subsequent event) and formed NRx Defense Systems, Inc. to pursue military-focused TMS applications.
- Financing: The company raised approximately $3.4 million in Q1 2026 via its At-The-Market (ATM) offering. Subsequent to the quarter end, an additional $7.0 million was raised via ATM.
- Risks: Key risks include the inability to secure additional financing, failure to obtain FDA approval for drug candidates, and the uncertainty of integrating acquired clinical operations.
Investor Verification Checklist
- Liquidity Runway: Verify the sufficiency of the $6.7 million cash balance against the $17.8 million working capital deficit and projected burn rate.
- Revenue Sustainability: Assess the scalability of the $1.1 million revenue from Dura Medical and the timeline for profitability in the clinical services segment.
- FDA Timelines: Monitor the status of the KETAFREE ANDA and the NRX-100 NDA filing in Q2 2026, as these are critical for future revenue.
- Warrant Liability Volatility: Note that the $3.5 million gain in Q1 2026 was non-cash and driven by warrant valuation changes; future earnings may be volatile based on stock price movements.
- Contingent Liabilities: Review the $5.6 million refund liability to Alvogen and the potential $3.0 million earn-out payment for the Dura acquisition.